Corticosteroid-binding globulin (CBG) is a blood plasma protein that transports the weakly water-soluble hormone, cortisol, throughout the circulation. It is a member of the serine protease inhibitor (SERPIN) structural family; upon cleavage by human neutrophil elastase, it undergoes the canonical S-to-R transition, which results in a change in its binding affinity for cortisol, allowing it to release the hormone at sites of inflammation. We plan to redesign CBG to transport compounds other than its physiological ligand and, by harnessing the S-to-R transition, release them at specific sites in the body.
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Acta Cryst. (2011) A67, C294 Dihydroorotate dehydrogenase (DHODH) catalyses the conversion of L-dihydroorote (DHO) to orotate, the fourth step and only redox reaction in the de novo pyrimidine biosynthetic pathway. The DHODHs can be divided into two major classes on the basis of their amino acid sequences and their cellular location. The enzyme dihydroorotate dehydrogenase (DHODH) has been considered a promising target for the design of trypanocidal agents. Interestingly, trypanosomatids and human DHODH have the different origins, belonging to families 1 and 2, respectively, and display structural differences that can be exploited for the development of selective drugs for the treatment of trypanosomal diseases.
Structure-based design of anti-trypanosomal drugs
It is our aim to contribute to the development of selective inhibitors for trypanosomal DHODHs. In order to achieve this goal, we have explored the human, T. cruzi and L. major enzymes, to guide the search for molecules that selectively bind to the trypanosomal enzymes, which is an important rationale behind the design of chemotherapeutic agents.
We report here the discovery of novel inhibitors of Trypanosomatids DHODH identified by virtual screening method and the crystal structure of these ligands in complex with DHODH from L. major. The crystal structure of DHODH from L. major was solved in the presence of different ligands. Monitoring of the enzymatic reaction in the presence of selected ligands together with structural information obtained from X-ray crystallography analysis have allowed the identification and validation of a novel site of interaction. Our results have provided important structural insights for the rational design of T. cruzi and Leishmania major DHODH inhibitors. Fumarate hydratases (FHs) catalyse the stereospecific reversible hydration of fumarate to malate. Eukaryotes express two isoforms of FH, the mitochondrial isoform which performs this reaction as part of the tricarboxylic acid cycle and as such is central to aerobic respiration and the cytosolic isoform which is thought to be involved in the metabolism of fumarate. As a first step aiming the validation of Leishmania major FH (LmFH) as target for drug design against leishmaniases, the recombinant enzymes have been used to perform kinetic, biophysical and structural characterization.
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Circular dichroism studies have identified differences in secondary structure content when comparing both isoforms and electron paramagnetic resonance approach has identified the presence of an ironsulfur cluster. In addition, significant differences in specific activities were found for both isoforms. Polyclonal antibodies have also been raised and subcellular localization studies for both isoforms indicated that one enzyme is localized in mitochondria, whereas the second isoform has double cytosol and glycosome localization. Crystallization and structural determination of LmFH isoforms are in progress.
Our results suggest that LmFH isoforms, which share around 60% of sequence identity, are localized in different cell compartments, and also display differences in protein folding and mechanism of action.
The results, here presented, correspond to the first studies on FHs from trypanosomatides, significantly contributing to the understanding of their functional role in Leishmania.
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Chemotherapy still constitutes the major pharmacologic approach against cancer. However, the biochemical repair systems of the cancer cell machinery responds, trying to mitigate the cellular damage induced by these agents. As a result, the clinical efficacy of chemotherapeutic agents is often limited. Several advances in the molecular biology of cancer have identified key pathways involved in the DNA repair of the damage induced by chemotherapeutic agents. Between all the mechanisms, we can highlight the base excision repair (BER) pathway. Apurinic/apyrimidinic endonuclease (APE-1) is one of the crucial enzymes in this mechanism. Due to its activity, further studies have been focused in the development of inhibitors for APE-1 enzyme. Here, we report the employment of docking and virtual screening techniques based in the crystallographic models to search for compounds that can act as APE-1 inhibitors. The discovered compounds have shown to be active in vitro assays, with activities between low and medium micromolar range. Currently, we are undertaking in vivo assays in order to determine their cytotoxicity and their effects in cancer cell survival. At the same time, we are in the process of solving the crystallographic structure of the complexes formed by APE-1 and each one of the active compounds in order to optimize their affinity for the target. The nitroreductase enzymes of E.coli have potential for use in Virus-Directed Enzyme Prodrug Therapy (VDEPT), converting the inactive prodrug CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide) to a potent difunctional alkylating agent [1] . The combination of the minor nitroreductase NfsB and the prodrug CB1954 has been put through Phase I/II clinical trials with promising results. The VDEPT uses an adenovirus vector to insert the gene encoding the nitroreductase into tumour cells, and then the prodrug is separately administered, and upon reaction first with the enzyme and subsequently with cellular thioesters, is transformed into a cell killing agent. This compound is able to transfer into nearby cells and kill those too, causing a 'bystander effect', which is essential for the effectiveness of the treatment. However for treatment to be successful greater efficacy is required.
The major limiting factor is the relatively poor affinity of NfsB for CB1954. Mutants of NfsB have been produced which bind more strongly to the prodrug. It has also been discovered that NfsA, the major E.coli nitroreductase, confers 3.5-8 times greater sensitivity to CB1954 than NfsB, in human cells and bacterial cells [2] . The crystal structures of two of the most active NfsB mutants, a double mutant (T41LN71S) and a triple mutant (T41QN71SF124T) are presented here in complex with different inhibitors and compared with wild-type [3] . These structures help us to understand the improvements in binding seen with these mutants. The cooperativity of the T41Q and F124T mutations is shown through a direct H-bonding interaction between the side chains and then to the inhibitor, providing an explanation for why the combination of these mutations has a greater effect than would be expected by the combination of the improvements seen with the single mutants alone.
Also presented are crystal structures of NfsA bound both to inhibitors and to a substrate, the antibiotic nitrofurantoin. The two nitroreductase enzymes are both homodimeric flavoenzymes, with two FMN containing active sites at the dimer interface. Despite having little sequence homology they do share several structural similarities. These structures can be used to guide future rational mutagenesis of the enzymes and design of improved prodrugs, ultimately creating an effective treatment method.
